# Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

**Authors:** Michel Alexander Steiner

PMC · DOI: 10.1038/s41531-024-00657-7 · 2024-03-14

## Full-text entities

- **Genes:** SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}
- **Diseases:** Parkinson's disease (MESH:D010300)
- **Chemicals:** minzasolmin (-)

---
Source: https://tomesphere.com/paper/PMC10940697